Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANI PHARMACEUTICALS INC Director's Dealing 2024

Jun 21, 2024

31676_dirs_2024-06-20_ce7ccbb9-1805-46b7-86b8-4aef835c8669.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2024-06-17

Reporting Person: Shanmugam Muthusamy (Director, HEAD OF R&D, COO-NOVITIUM OPS)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-06-17 Common Stock S 7946 $61.41 Disposed 724674 Indirect
2024-06-18 Common Stock S 10607 $60.76 Disposed 714067 Indirect
2024-06-20 Common Stock S 11447 $59.86 Disposed 702620 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 68652 Direct
Common Stock 5000 Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F2: The shares were sold in multiple trades at prices ranging from $60.77 to $62.55. The price reported above reflects the weighted average sales price.

F3: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

F4: The shares were sold in multiple trades at prices ranging from $60.33 to $61.82. The price reported above reflects the weighted average sales price.

F5: The shares were sold in multiple trades at prices ranging from $59.40 to $60.50. The price reported above reflects the weighted average sales price.

F6: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.